Georg Schroeckenfuchs

With over 30 years of experience, Schroeckenfuchs has been leading Novartis’ operations in the MENA region for two years. His role is to attract investments to drive growth and his scope was extended to include South Africa this year, forming Novartis MEA. Under his leadership, the firm achieved 6.2% growth in the first half of 2020 compared to 2019, while the market grew by 2%. Novartis is committed to accelerating cell and gene therapy in MEA once it has FDA approval. Therapy for treating inherited blindness in children is now available in the U.A.E. and Saudi Arabia.